Tradestie Institutional Equity Comparison Engine

FGEN vs AKRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-01-07 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AKRO Overall Edge

AKRO Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“5 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Akero Therapeutics, Inc. Common Stock (AKRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while FGEN counters with relative strength in Valuation. Fundamentally, FGEN trades at 61.4x Forward P/E with -499.1% operating margin (+774.8% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, FGEN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner FGEN
FGEN 61.4x vs AKRO N/M Fwd P/E
Growth & Margin Winner AKRO
Op Margin -499.1% vs 0.0% ยท YoY +774.8% vs +0.0%
Momentum & Technical Winner AKRO
1Y -28.8% vs +76.8% ยท 52W Pos 44% vs 90%
Options & Structure Winner AKRO
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (30th %ile IV)
FGEN NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
1M Return +16.57%
1Y Return -28.84%
Forward P/E 61.4x
Unified AI Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FGEN -28.84% AKRO +76.75% Spread: +132.25 pp (AKRO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
FGEN TTM Op. Margin: -499.1% AKRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FGEN vs AKRO. Trailing 12-month operating profitability (FGEN -499.1% vs AKRO 0.0%) and valuation multiples (FGEN 61.4x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FGEN (5) vs AKRO (5)
Institutional Metric FGEN AKRO Criterion Row Winner
Market Capitalization Scale $36.5M $4.5B Larger Scale AKRO
Trailing P/E Ratio Valuation 61.4x N/M Lower Multiple FGEN
Forward P/E Ratio Valuation 61.4x N/M Lower Multiple FGEN
Revenue Growth (YoY) Growth +774.8% +0.0% Higher Growth FGEN
Operating Margin (TTM) Profitability -499.1% 0.0% Higher Margin AKRO
Net Profit Margin Profitability 2598.9% 0.0% Higher Margin FGEN
Return on Equity (ROE) Capital Efficiency -1015.8% -34.5% Higher ROE AKRO
52-Week Range Position Momentum 44% ($0โ€“$22) 90% ($21โ€“$58) Stronger Trend AKRO
Beta / 30D Volatility Risk Regime -20.79ฮฒ ยท 102% Vol 0.90ฮฒ ยท 2% Vol Lower Realized Risk AKRO
Unified Institutional Score Composite Signal 61.2 / 100 (BUY) 60.0 / 100 (BUY) Higher Composite FGEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FGEN vs AKRO Buy Guide
FGEN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live FGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FGEN nor AKRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.